{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-078152","form_type":"8-K","ticker":"OSTX","cik":"0001795091","company_name":"OS Therapies Inc","filed_at":"2025-08-19T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.016318+00:00","generated_at":"2026-05-17T11:30:54.842343+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"OS Therapies Q2 net loss $4.5M; FDA confirms RMAT, issues BLA number for OST-HER2, Phase 2b data positive","bullets":["FDA confirmed OST-HER2 meets biological criteria for RMAT; issued BLA number for Accelerated Approval submission.","Phase 2b trial: 12-month EFS 35% vs 20% (p=0.0197), interim 2-year OS 66.6% vs 40% (p=0.0046).","Q2 2025 net loss $4.537M vs $1.557M YoY; EPS loss $0.19 on 25.1M shares vs $0.26 on 5.99M shares.","End of Phase 2 FDA meeting scheduled Aug 27, 2025; projected rolling BLA submission late Q3 2025.","$4.2M capital raise closed July 11; entered ATM offering up to $18M; commercial partner Eversana for possible 1H 2026 launch."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-078152","json":"https://secwatch.observer/filing/0001213900-25-078152.json","markdown":"https://secwatch.observer/filing/0001213900-25-078152.md","text":"https://secwatch.observer/filing/0001213900-25-078152.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1795091/000121390025078152/0001213900-25-078152-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1795091/000121390025078152/ea0253711-8k_ostherap.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T11:30:54.842343+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}